Using artificial intelligence to improve treatment decisions for skin cancer
Improving prognosis prediction and therapy selection for cutaneous squamous cell carcinomas using artificial intelligence
['FUNDING_R21'] · DANA-FARBER CANCER INST · NIH-10988558
This study is looking at a common skin cancer called cutaneous squamous cell carcinoma (cSCC) to help doctors better predict how patients will do and choose the best treatments for them, using smart computer technology to analyze tumor information and improve care for everyone.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10988558 on ClinicalTrials.gov |
What this research studies
This research focuses on cutaneous squamous cell carcinoma (cSCC), a common type of skin cancer, and aims to enhance how doctors predict patient outcomes and select therapies. By developing advanced artificial intelligence algorithms, the project will analyze a large dataset of cSCC tumors, including their histopathology and clinical outcomes. The AI models will help identify patients at higher risk for severe disease, allowing for more tailored and effective treatment plans while minimizing unnecessary side effects for those at lower risk.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cutaneous squamous cell carcinoma who may benefit from personalized treatment strategies.
Not a fit: Patients with other types of skin cancer or those whose cSCC is already at an advanced stage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate treatment decisions for patients with cutaneous squamous cell carcinoma, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promise in using artificial intelligence for cancer prognosis and treatment selection, indicating that this approach could be effective.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LOTTER, WILLIAM EDWARD — DANA-FARBER CANCER INST
- Study coordinator: LOTTER, WILLIAM EDWARD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.